4 result(s) for 'CDX2'
1 - 4 of 4 results for 'CDX2'
Sort by
Show
Antigen Background
CDX2は、腸の発生初期に発現する腸特異的転写因子のcaudal 型ホメオボックスであり、腸上皮細胞の増殖および分化の調節に関与している可能性があります。腸はCDX2とCDX1のいずれかの遺伝子産物を検出可能レベルで含む唯一の器官であるため、CDX2はCDX1とともに関心を集めています。この限定された発現パターンはホメオボックス遺伝子ではあまりみられません。CDX2活性化ドメインのリン酸化が、腸上皮におけるCDX2の機能と発現パターンを調節している可能性があります。CDX2は、主に絨毛の表面および陰窩に発現します。CDX1とは対照的に、CDX2は発生過程にある遠位部を除く腸に強く発現することが報告されています。CDX2の欠失は、一部の散発性大腸癌の進行に関わることが報告されています。また、CDX2が胃の発癌に関連している可能性もあり、胃癌細胞の分化が低くなるにつれてCDX2 mRNAの発現が次第に減少することも報告されています。
Disclaimer...
Slide 1
Hello, hello; thank you so much for that introduction. Let's get started. Oh, I'm sorry, I just need to hit this next button here. So my name is Mark Lawson.
Thank you for joining us in this webinar. I'm here to present BOND RX tips, tricks, and optimization. It's going to be a user guide from the BOND RX and chromogenic multiplexing in the research application.
Slide 2
So, my name is Mark Lawson. I'm an application specialist on the Life Sciences team at Leica Biosystems I provide technical support for the Life Sciences portfolio, including but not limited to the BOND RX, the BOND RXm, and a wide array of reagents. So I've worked in the histology field for about 15 years and in both clinical and research spaces. I started off as a histotechnologist and worked my way up...
It’s Time for TIME Alexander “Sandy” Borowsky Professor of Pathology and Laboratory Medicine Center for Immunology and Infectious Diseases
Disclosures Bristol-Meyers Squibb/Celgene: Funded through Investigator Sponsored Research (ISR) program. Discovery proposal. Leica/Aperio: Funded to run the “Genesis” study for primary diagnosis from whole slide images. Honorarium for this presentation. Histolix: Slide-free histology (Levenson and Fereidouni). Pfizer: Pfizer Protocol A9001502, Treatment Resistance Following Therapies (TRANSLATE) site PI. Agenda: In contracting to join the “FLEX” registry. None of these has actually paid me, only funding for the research projects.
Objectives • Introduction into the complexity of the TIME and the development of new cancer treatments though di...
Biomarkers
AE1/AE3 (1)
AMACR (2)
BCL6 (1)
CD163 (2)
CD20 (2)
CD3 (9)
CD4 (5)
CD68 (5)
CD8 (10)
CDX2 (2)
CK20 (5)
Ck5 (4)
...